Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 891065 in Advanced or Metastatic Solid Tumors
NCT03166631Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2017
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 891065 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Sep 2017; status: terminated.
02
Drugs
BI 891065
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03166631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166631.